PRIMARY STUDY
The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases.
Key Findings: In various mouse and rat models of obesity and type 1 and 2 diabetes mellitus, eCBs generated in various renal cells activate CB1 receptors and contribute to the development of oxidative stress, inflammation, and renal fibrosis. These effects can be chronically ameliorated by CB1 receptor blocker. In contrast, activation of the renal CB2 receptors reduces the deleterious effects of these chronic diseases.
Type of Study: Meta-analysis
Study Result: Positive
Study Location(s): Israel
Year of Pub: 2015
Cannabinoids Studied: AM-x Synthetic Cannabinoids, SR-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Endocannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Terpenes Studied: ß-Caryophyllene
Receptors Studied: CB1, CB2
